Treatment Strategies for Cardiomyopathies
For hypertrophic cardiomyopathy with obstruction, start with beta-blockers or non-dihydropyridine calcium channel blockers, then add mavacamten or disopyramide if symptoms persist, and reserve septal reduction therapy for refractory cases at experienced centers. 1, 2, 3
Hypertrophic Cardiomyopathy (HCM)
Obstructive HCM Treatment Algorithm
First-line pharmacotherapy:
- Non-vasodilating beta-blockers (metoprolol preferred - superior gradient reduction and symptom improvement) 3
- OR non-dihydropyridine calcium channel blockers (verapamil, diltiazem) - use cautiously with very high gradients due to vasodilatory effects 2, 3
- Avoid carvedilol and labetalol (arterial vasodilation worsens obstruction) 3
Second-line options for persistent symptoms:
- Mavacamten (myosin inhibitor) - highly effective and well-tolerated in adults with obstructive HCM 1, 3
- Disopyramide (class 1A antiarrhythmic) - must be combined with AV nodal blocking agent 1, 2
Invasive septal reduction therapy:
- Reserved for severe symptoms despite maximal medical therapy 1, 2
- Must be performed at high-volume expert centers (mortality <1%, success >90-95%) 2
- Options: surgical myectomy (broader applicability) or alcohol septal ablation 2, 3
Nonobstructive HCM
- Beta-blockers or calcium channel blockers for symptom management 2, 3
- Diuretics if elevated filling pressures present 3
- For younger patients (≤45 years) with mild phenotype and sarcomere variant: Valsartan may slow adverse remodeling 1
- Myosin inhibitors under investigation in clinical trials 3
HCM with Reduced Ejection Fraction
- Poor prognosis - early referral for advanced heart failure therapies essential 3
- Apply guideline-directed medical therapy for heart failure with reduced ejection fraction 3
- Discontinue cardiac myosin inhibitors immediately 1
Lifestyle and Risk Stratification
- Vigorous recreational activity is reasonable after annual comprehensive evaluation - universal restriction not indicated 1
- ICD placement: Discuss 5-year sudden death risk for patients with ≥1 major risk factor using validated risk scores 1
- Annual extended ambulatory monitoring for high-risk patients eligible for anticoagulation (upgraded from periodic to annual screening) 1
Critical Pitfalls to Avoid
- Do not use diuretics aggressively (decreases preload, worsens obstruction) 2
- Avoid vasodilators, positive inotropes, and high-dose diuretics in symptomatic obstruction 2
- Counsel patients on hydration, avoiding hot environments (saunas, hot tubs), and caution with sildenafil, nitrates, and alcohol 3
Dilated Cardiomyopathy (DCM)
Apply standard guideline-directed medical therapy for heart failure with reduced ejection fraction, including ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. 4, 5
Pharmacological Management
Core medications (Class I evidence):
- ACE inhibitors or ARBs (angiotensin receptor blockers) 4, 6
- Beta-adrenergic antagonists (carvedilol, metoprolol succinate, bisoprolol) 4, 6
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone) 4, 6
- Diuretics for volume management 4
- Digoxin for symptom control 4
High-quality evidence from umbrella review:
- Atorvastatin: Improves LVEF, reduces CRP, systolic BP, and LVEDD 7
- Carvedilol: Significantly improves LVEF and cardiac output 7
- Thyroid hormone: Improves LVEF in select patients 7
- L-carnitine: Reduces left ventricular volumes 7
Device Therapy
- ICD for primary prevention: LVEF ≤35% on optimal medical therapy for ≥3 months (NYHA class II-III) 6
- Cardiac resynchronization therapy (CRT): LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms, NYHA class II-IV on optimal therapy 6
Advanced Therapies
- Revascularization: Consider CABG if significant multivessel CAD with viable myocardium 6
- Mechanical circulatory support: Bridge to transplant or destination therapy for advanced refractory heart failure 6
- Heart transplantation: Definitive therapy for end-stage disease 6
Emerging Evidence
Traditional Chinese medicines combined with Western therapy (high-quality evidence):
- Qili Qiangxin capsule, Shenmai injection, Zhigancao, Shengmai significantly improve LVEF, 6-minute walk distance, reduce LVESD, LVEDD, and inflammatory markers 7
Stem cell therapy:
- High-quality evidence shows improvement in LVEF, ejection volume, 6-minute walk distance, and NYHA class 7
Restrictive Cardiomyopathy (RCM)
Identify and treat the underlying cause through endomyocardial biopsy when secondary forms are suspected, as treatment is etiology-specific. 5
Diagnostic Approach
- Characteristic findings: Enlarged atria, normal ventricular dimensions, preserved systolic function, dip-plateau hemodynamic pattern 8
- Endomyocardial biopsy is pivotal to identify secondary causes (amyloidosis, sarcoidosis, hemochromatosis, etc.) 8
Management Strategy
Treat underlying disease specifically:
- Cardiac amyloidosis: Tafamidis for ATTR, chemotherapy for AL amyloidosis
- Hemochromatosis: Phlebotomy, iron chelation
- Sarcoidosis: Corticosteroids, immunosuppression
Symptomatic heart failure management:
Arrhythmia management: High incidence of atrial fibrillation requires anticoagulation and rate control 9
Advanced therapies: Heart transplantation for refractory cases without systemic contraindications 6
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
All patients with ARVC should receive an ICD if they have survived cardiac arrest or sustained ventricular tachycardia, avoid strenuous sports, and be referred to an experienced center. 10
Diagnosis
- Suspect ARVC in: Unexplained RV dilation/dysfunction with ventricular arrhythmia, syncope, heart failure, characteristic ECG changes, or positive family history 10
- Apply ESC/International Society criteria for diagnosis 10
- Imaging: Echocardiography or CMR mandatory (CMR interpretation requires experienced centers) 10, 11
- Endomyocardial biopsy: High perforation risk - only at experienced centers with extreme caution 10
Management
ICD therapy (primary treatment goal is sudden cardiac death prevention):
- Class I indication: Cardiac arrest survivors or sustained ventricular tachycardia history 10, 8
- Class IIa indication: High-risk patients for sudden cardiac death prevention 10
- Superior to pharmacological approaches for preventing sudden death 8
Activity restriction:
- Mandatory avoidance of strenuous or high-intensity sports 10
Antiarrhythmic drugs or catheter ablation:
- Not substitutes for ICD therapy 10
- May be considered for patients refusing or ineligible for ICD, or to reduce ICD shocks 10
Genetic considerations:
- Genetic testing for families recommended for screening and counseling 10
- Up to 40% may have normal ECG initially, but almost all develop pathological changes within 6 years 10
Referral:
- All patients must be referred to centers with ARVC expertise 10
Cross-Cutting Principles
Atrial Fibrillation Management
Cardiomyopathy patients with AF require aggressive anticoagulation even for brief episodes, particularly in HCM and amyloidosis. 9
- AF prevalence highest in HCM and DCM 9
- Traditional risk scores not validated in cardiomyopathies - use comprehensive risk stratification 9
- Early oral anticoagulation initiation for brief AF episodes in HCM and amyloid cardiomyopathy 9
- Genotype-tailored approach needed for DCM and NDLVC (laminopathies, neuromuscular diseases have higher AF burden) 9
Genetic Testing and Family Screening
- Prioritize genetic testing when results impact management, family screening, or prognosis 11
- High-yield scenarios: Familial sudden cardiac death, extensive late gadolinium enhancement, conduction disorders 11
- ECG and echocardiography fundamental for family screening 11